RT Journal Article
SR Electronic
T1 Impact of weight-bearing and sex-stratified differences in risk factors of bone loss on bone mineral density in HIV conditions – findings of the Nigeria HIV-BMD study: An observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.13.22281045
DO 10.1101/2022.10.13.22281045
A1 Ibeneme, Sam Chidi
A1 Fortwengel, Gerhard
A1 Okoye, Ifeoma Joy
A1 Okenwa, Wilfred Okwudili
A1 Ezuma, Amarachi Destiny
A1 Nwosu, Akachukwu Omumuagwula
A1 Ibeneme, Georgian Chiaka
A1 Nnamani, Amaka
A1 Limaye, Dnyanesh
A1 Fneish, Firas
A1 Myezwa, Hellen
A1 Philip, Okere
A1 Iloanusi, Nneka
A1 Ajidahun, Adedayo Tunde
A1 Ulasi, Ifeoma
YR 2022
UL http://medrxiv.org/content/early/2022/10/14/2022.10.13.22281045.abstract
AB Background Biomechanical loading exerts an osteogenic stimulus; thus, bone mineral density(BMD) may vary in weight-bearing and non-weight-bearing bones. Therefore, weight-bearing activities could modulate sex-, HAART- and HIV-related BMD loss.Method A cross-sectional observational study of 503 people living with HIV (PLWH) selected by convenience sampling at Enugu State University Teaching Hospital, Nigeria, was conducted from September 2015 to September 2016. The BMD of toe or weight-bearing(BMDtoe) and thumb or non-weight-bearing(BMDthumb) bones were measured with Xrite 331C densitometer and compared using independent t-test. Impact of the risk factors (age, weight, body mass index-BMI, duration of HIV, height and types of HAART) of bone loss and their relationships with the BMD were compared across the sexes using multivariate, and univariate regression analyses, at p<0.05,two-tailed.Result Participants comprised of females(378/75.1%), males(89/17.7%) and others(36/7.16%) without gender specificity, with mean age=37.2±9.79years, and BMI=25.6±5.06kg/m. HAART-experienced participants’ (352/69.98%) mean HAART-exposure duration was 4.54±3.51years. BMDtoe(−0.16±0.65g/cm3) was higher(p<0.05) than BMDthumb(−0.93±0.44g/cm3), and differed across the BMI classes (p=0.000003;d=0.998), and was accounted for in post hoc analysis by normal weight versus underweight BMI classes (p=<0.001). BMDtoe was positively correlated with height (r=0.13,r2=0.0169;p<0.05), and males were taller than females(p<0.001). Females accounted for 90%(9/10) cases of osteopenia and 71.43%(5/7) osteoporosis. Males were older(p=0.002) while females had greater BMI (p=0.02), lower median BMDtoe(p=0.005) and BMDthumb (p=0.005).Conclusion Higher BMD in weight-bearing bones, and lower BMDtoe in underweight (sub-optimal loading) BMI class suggest a role for osteogenic stimulus and fat metabolism in bone loss. Females being younger/heavier, would have greater loading/osteogenic stimulus reinforced by lesser age-related BMD changes. Males being taller would have greater bone marrow adipose tissue that promote osteogenesis through paracrine mechanisms. Therefore, higher BMD in males should be partly explained by height-related metabolic surrogates and sex-hormonal differences. Greater BMD In females’ weight-bearing bones implies that loading ameliorates physiological tendencies towards lower BMD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Nigeria Health Research Ethics Committee on certificate number – NHREC/05/01/2008B.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe datasets generated and analyzed during the current study are not publicly available due to ethical concerns as the data contain potentially identifying and sensitive patient information but are available from the corresponding author and first author upon reasonable request.